New Jersey touts biotech growth
A new survey of New Jersey's biotech industry has found that the drug development business is growing steadily. Combined public and private biotech revenue was set at $5 billion from 238 biotech companies in the state--up from 226 in 2006. And 86 percent of the surveyed companies said they expect to hire 20 or more employees in the next 12 months. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
